Precision antimicrobial agents
ABAC Therapeutics is committed to finding therapeutic solutions for patients that are infected with highly antibiotic-resistant bacterial pathogens and that leave affected patients with few (or no) treatment options. Heads of national healthcare services, professional infectious diseases organizations and infectious diseases experts are warning that we facing a return to a pre-antibiotic era. Infections with such “superbugs” are increasing in both severity and frequency, and new drugs are needed to treat them now.
Decrease length of stay in the hospital by increasing efficacy.
ABAC Therapeutics’ first targets of highest urgency are the infections caused by the “Big Four” Gram-negative bacteria: Pseudomonas aeruginosa, Acinetobacter baumanii, Klebsiella pneumoniae, and Escherichia coli. But the pathogen-specific principle applies to all bacteria species.
The ABAC Therapeutics Vision
We need targeted antibiotics that kill specific pathogens irrespective of where in the body they are causing disease, rather than general agents that kill any pathogen in a particular body site. Soon, point of care diagnostic techniques will be rapid, cost-effective and widely used. Precision antimicrobial agents (pathogen-specific and narrow spectrum) will replace broad spectrum antibiotics.
Domingo Gargallo-Viola, 2008
Precision treatments of serious bacterial infections with pathogen-specific, novel-mechanism antibacterials that selectively eliminate the targeted pathogen while sparing the normal flora and minimizing the selective pressure on non-targeted strains